International multicenter experience in the treatment of invasive aspergillosis in immunocompromised cancer patients

CONCLUSIONS:Based on international experience in immunocompromised cancer patients with IA, primary therapy with voriconazole-containing regimen is associated with improved response and survival compared with non-voriconazole amphotericin B based regimen.
Source: Mediterranean Journal of Hematology and Infectious Diseases - Category: Hematology Source Type: research